RLMD
Relmada Therapeutics, Inc.
Biotechnology · Healthcare · United States
3.58
close · 2026-10-30
value
32
cheaper than peers32
quality
95
stronger fundamentals95
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | -12.0% | 61 |
| price to book | 1.85× | 60 |
| cash flow yield, 1 year ago | -13.6% | 54 |
| cash flow yield, 2 years ago | -13.5% | 52 |
| earnings yield, latest year | -40.5% | 38 |
| earnings yield, 2 years ago | -91.6% | 36 |
| cash flow yield, 3 years ago | -27.2% | 35 |
| earnings yield, 1 year ago | -74.0% | 29 |
| earnings yield, 3 years ago | -148.0% | 28 |
| EV to EBITDA | 3.98× | 19 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.1% | 95 |
| return on equity | -25.6% | 92 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $382M |
| free cash flow | -$7.7M |
| employees | 17 |
| first trade | 2014-06-20 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.45 | -2.65 | -3.28 | -5.30 |
| free cash flow | -$45.8M | -$51.8M | -$51.7M | -$103.8M |
| net income | -$57.4M | -$80.0M | -$98.8M | -$157.0M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | $319,048 | $381,661 | -$241,157 | -$4.8M |